Li Ma
- Cancer Research top 0.05%
- Cancer-related molecular mechanisms research 25
- MicroRNA in disease regulation 24
- Molecular Biology top 0.2%
- RNA modifications and cancer 31
- Ubiquitin and proteasome pathways 16
- Epigenetics and DNA Methylation 15
- RNA Research and Splicing 14
- Oncology top 0.5%
- Cancer-related Molecular Pathways 14
- Immunology top 1%
- Genetics top 1%
-
- Platelet Disorders and Treatments 19
- Co-authors
- Julie Teruya‐FeldsteinRobert A. WeinbergYutong SunPier Paolo PandolfiPeijing ZhangZhenbang ChenPaul TempstHediye Erdjument‐Bromage
- Partner nations
- ChinaUnited StatesJapan
In The Last Decade
Li Ma
251 papers receiving 18.2k citations
Hit Papers
Peers
Comparison fields: 5 of 165
- Cancer Research 7.6k
- Molecular Biology 13.5k
- Oncology 3.0k
- Immunology 1.6k
- Genetics 773
Countries citing papers authored by Li Ma
This map shows the geographic impact of Li Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Li Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Li Ma more than expected).
Fields of papers citing papers by Li Ma
This network shows the impact of papers produced by Li Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Li Ma. The network helps show where Li Ma may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Li Ma, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 9 | |
| 4 | 2024 | 12 | |
| 5 | 2024 | 7 | |
| 6 | 2024 | 27 | |
| 7 | 2023 | 22 | |
| 8 | SLC7A11 expression level dictates differential responses to oxidative stress in cancer cellsbreakdown → | 2023 | 176 |
| 9 | 2022 | 17 | |
| 10 | 2022 | 4 | |
| 11 | 2022 | 16 | |
| 12 | 2022 | 2 | |
| 13 | 2021 | 75 | |
| 14 | 2021 | 17 | |
| 15 | 2020 | 31 | |
| 16 | 2018 | 138 | |
| 17 | Long noncoding RNA MALAT1 suppresses breast cancer metastasisbreakdown → | 2018 | 546 |
| 18 | 2016 | 78 | |
| 19 | 2015 | 106 | |
| 20 | 2014 | 108 |
About Li Ma
Li Ma is a scholar working on Cancer Research, Molecular Biology and Hematology, having authored 260 papers that have together received 18.4k indexed citations. Recurring topics across this work include RNA modifications and cancer (31 papers), Cancer-related molecular mechanisms research (25 papers), MicroRNA in disease regulation (24 papers), Platelet Disorders and Treatments (19 papers), Ubiquitin and proteasome pathways (16 papers), Epigenetics and DNA Methylation (15 papers), Cancer-related Molecular Pathways (14 papers) and RNA Research and Splicing (14 papers). The work is most often cited by research in Cancer Research (7.6k citations), Molecular Biology (13.5k citations) and Oncology (3.0k citations). Li Ma has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Julie Teruya‐Feldstein, Robert A. Weinberg, Yutong Sun, Pier Paolo Pandolfi, Peijing Zhang, Zhenbang Chen, Paul Tempst, Hediye Erdjument‐Bromage, Jongchan Kim and Ferenc Reinhardt. Their work appears in journals such as Nature Communications, Cancer Research, Cancers, Nature Cell Biology and Biochemical and Biophysical Research Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.